ArticleFrontiers in immunology2024
Integrating omics data and machine learning techniques for precision detection of oral squamous cell carcinoma: evaluating single biomarkers.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Established machine learning matches tabular foundation models in clinical predictions.BMC medical informatics and decision making · 2026Article
- Identification and Validation of a Lipid Metabolism-Related Gene Signature for Predicting Prognosis and Immunotherapy Response in Oral Squamous Cell Carcinoma.Metabolites · 2026Article
- dbGVOSCC: a comprehensive database of genetic variation for systems genetics research on oral squamous cell carcinoma.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early detection of oral squamous cell carcinoma (OSCC) is critical for improving clinical outcomes. Precision diagnostics integrating metabolomics and machine learning offer promising non-invasive solutions for identifying tumor-derived biomarkers. Methods: We analyzed a multicenter public dataset comprising 61 OSCC patients and 61 healthy controls. Plasma metabolomics data were processed to extract 29 numerical and 47 ratio features. The Extra Trees (ET) algorithm was applied for feature selection, and the TabPFN model was used for classification and prediction. Results: The model achieved an area under the curve (AUC) of 93% and an overall accuracy of 76.6% when using top-ranked individual biomarkers. Key metabolic features significantly differentiated OSCC patients from healthy controls, providing a detailed metabolic fingerprint of the disease. Discussion: Our findings demonstrate the utility of integrating omics data with advanced machine learning techniques to develop accurate, non-invasive diagnostic tools for OSCC. The study highlights actionable metabolic signatures that have potential applications in personalized therapeutics and early intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.